explore -WSS

explore

author：entertainment 2025-10-03 00:39:22 - browse：214

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why scientists need input from humanists on sensitive research

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

Medical records are filled with copy

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Medicare details structure of new drug price negotiation program

Jerome Adams on the need for new antivirals for Covid

UCLA team creates talking throat patch for voice disorders

leisure time

explore

Gilead needs Arcellx more than ever

focus

Sports medicine is finally prioritizing gender equality

Cancer drug shortages should be causing more outrage

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Novavax promises a turnaround & Lilly roils the obesity market

23andMe had bad news about my health. I wish a person had delivered it

State Dept. review finds Biden bears some blame for Afghanistan failures

Peter Hotez and the public health issue of online harassment

Duchenne breakthrough therapy leaves behind pioneering families

Cancer drug shortages should be causing more outrage

Continuity nursing helped my family in our darkest PICU moments

explore

WuXi out of biotech trade group, U.S. and China relations to blame

Dobbs anniversary: the lost opportunity of abortion as health care

Amid AI frenzy, a top HHS official's quest to create safeguards

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Bristol, Sangamo, Gilead, and more

entertainment

entertainment

knowledge

hotspot